Clinical Trial Update: A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission [Phase 1]

View source ↗

Summary

Phase 1 study of CSL362 for CD123-positive acute myeloid leukemia in remission has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CSL362 (talacotuzumab)

Snippet

Sponsor: CSL Limited | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED